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Review Article
Wilson's Disease: a review    
A. Hassan, F. Masood
Departments of Medicine and Pediatrics*, The Aga Khan University Hospital, Karachi.
Introduction and Genetics
Wilson's disease (WD; Hepatolenticular degeneration)
is an autosomal-recessive disorder of copper metabolism
due to absence or dysfunction of a copper-transporting, P-
type ATPase which is essential for the transport of copper
into bile. Affected patients accumulate excessive copper
within the liver as well as the brain and other tissues. This
is mainly a disease of children, adolescents, and young
adults, and is characterized by hepatobiliary, neurologic,
psychiatric and ophthalmologic (Kayser-Fleischer rings)
manifestations.  If diagnosed early and properly managed,
WD is one of the more easily treated inborn errors of metab-
olism. In 1912, Samuel Alexander Kinnier Wilson (British
Neurologist, 1878-1937), while serving as a Senior
Resident at the National Hospital for Nervous Diseases,
London, published his experience of "Progressive Lenticular
Degeneration: A Familial Nervous Disease Associated with
Cirrhosis of the Liver", as part of his dissertation for the MD
degree.1 He speculated that the brain disease characterized
by extra pyramidal features was caused by the liver disease. 
The discovery of the gene for Menkes' disease and
its product ATP7A, a cation-transporting P-type adenosine
triphosphatase (ATPase) involved in copper transport in
many tissues, 2 was a breakthrough in the understanding of
the molecular basis of the defect of copper metabolism in
Wilson's disease. Just after this discovery, Wilson's disease
was identified as the result of a defect in a gene, designated
ATP7B that encodes a copper transporting P-type ATPase.3
WD occurs worldwide with an average prevalence of ~ 30
affected individuals per million populations.4 Table I gives
the description of milestone of WD.
Pathophysiology
Wilson's disease is a disease of copper toxicity.
Absorbed dietary copper is bound mainly to albumin in the
portal circulation from which it is avidly extracted by hepa-
tocytes. Hepatocellular copper is subsequently used for cel-
lular metabolic needs, incorporated into ceruloplasmin or
excreted into bile.  The transport of hepatocellular copper to
bile is thought to involve a vesicular pathway (Golgi appa-
ratus) that depends on ATP7B (copper transporting P-type
ATPase) function.4 The absence or diminished function of
ATP7B results in a decrease in biliary copper excretion,
which is responsible for the hepatic accumulation of this
metal in Wilson's disease.
Initially the copper is stored in the liver, when it
accumulates beyond the cellular capacity for its safe stor-
age, hepatocellular injury may result. Toxic effects of
excess copper  include  the generation of free radicals, lipid 
peroxidation of membranes and DNA, inhibition of protein
synthesis and altered level of cellular antioxidants. When
storage capacity of the liver for copper is exceeded or when
hepatocellular damage occurs, unbound copper splits out of
liver and finds its way to other organs and tissues where it
also begins to accumulate. The brain is the most important
site for the extrahepatic accumulation of copper.
Ceruloplasmin (a serum glycoprotein) is synthesized
predominantly in the liver and functions as the major carri-
er for copper in the blood. Majority of patients with
Wilson's disease have low ceruloplasmin levels due to
decreased rate of synthesis of the ceruloplasmin molecules
in the liver. Hypoceruloplasminemia has no primary role in
the pathogenesis of Wilson's disease. Copper is thought to
be incorporated into ceruloplasmin in the Golgi apparatus,
and during the biosynthetic process of ceruloplasmin, newly
transported copper must also cross Golgi apparatus mem-
brane which is again ATP7B dependant and which is absent
or diminished in most of the Wilson's disease patients.5 A
reduction of the incorporation of copper into ceruloplasmin
is believed to lead to a reduced circulating level of this pro-
tein. Other conditions associated with ceruloplasmin defi-
ciency are hereditary ceruloplasmin deficiency, Menkes'
disease, and conditions with transient ceruloplasmin defi-
ciency (such as protein losing enteropathy, nephritic syn-
drome, hepatic failure, sprue, etc).6
Clinical Manifestations 
Wilson's disease is most frequently recognized as a
trait of liver disease, neurological symptoms, and K-F rings.
Nevertheless, because multiple organ system can be affect-
ed with excessive copper accumulation, Wilson's disease is
remarkable clinical heterogeneity and patients may present
in a number of different ways. Generally, in children the
liver is chiefly involved, later neuropsychiatric features
become increasingly important. While patients presenting
after age 20 years usually have neurological symptoms. The
two types may overlap. The spectrum of WD is summarized
in Table 2. 
The average age of the patients whose first present-
ing symptoms of their WD are either neurological or psychi-
atric, is frequently later than those presenting with hepatic
symptoms (18 years versus 11.4 years), although neurolog-
ical symptoms have been reported as early as age 6 and as
late as age 50.8 WD is a disease of motor function, and basal
ganglia symptoms are the most common symptoms. The
prevalence of seizures is 10 times higher in patients with
WD that in the general population. The psychiatric features
of WD are under-appreciated and often misdiagnosed as
having primary psychosis or schizophrenia. More than 20
percent patients with WD were found to have sought psy-
chiatric evaluation before the diagnosis.9
Hepatic manifestation is more common in child-
hood, although it has been documented in patients beyond
age 40.11 Thus in patients between age 40 and even 50 who
present with hepatic dysfunction, WD should be considered
in the differential diagnosis. The clinical spectrum of liver
disease associated with WD ranges widely. The type of the
liver disease can be highly variable, ranging from asympto-
matic with only biochemical abnormalities to fulminant
hepatic failure. Hepatocellular carcinoma is very rare and
copper may be protective.12
Kayser-Fleischer (KF) rings: These represent copper
deposition on Descemet's membrane at the limbus of cornea
are almost always bilateral, but unilateral KF rings have
been described.13 KF rings are not pathognomonic of WD,
since they can be seen in other non-Wilson's hepatic condi-
tions including primary biliary cirrhosis, chronic active hep-
atitis, possible partial biliary atresia, cirrhosis and chronic
cholestatic jaundice.14 Sun-flower cataracts, another oph-
thalmologic change, much less common then KF rings,  rep-
resent deposits of copper in the lens.
Both Kayser-Fleischer rings and sun-flower
cataracts will gradually disappear with effective medical
treatment or following liver transplantation, although the
rate of disappearance does not correlate with resolution of
clinical symptoms. The reappearance of either of these oph-
thalmologic findings in a medically treated patient in whom
these had previously disappeared, suggests noncompliance
with therapy.
Diagnostic Testing
The most important single factor in early diagnosis
of WD is suspicion of the disease, when the diagnosis is not
considered, it will not be made. WD should be considered
and excluded in any individual between the age of 3 and 40
years with unexplained neurological (especially with
extrapyramidal or cerebellar motor disorder), hepatic, or
psychiatric dysfunction with or without family disorder of
neurological or hepatic disease. 
Slit lamp Examination 
All suspected WD patients should undergo a slit-
lamp examination by an experienced ophthalmologist for
the detection of KF rings. KF rings are almost invariably
present in patients with a neurological presentation, but
even in these patients they may not be found in 5%.15 Large
series of patients with WD show that KF rings are present in
only 50% to 62% of patients with mainly hepatic disease at
the time of diagnosis.16
24 Hour Urinary Copper
Very useful and relatively simple screening test for
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Diagnostic Testing
The most important single factor in early diagnosis
of WD is suspicion of the disease, when the diagnosis is not
considered, it will not be made. WD should be considered
and excluded in any individual between the age of 3 and 40
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extrapyramidal or cerebellar motor disorder), hepatic, or
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Slit lamp Examination 
All suspected WD patients should undergo a slit-
lamp examination by an experienced ophthalmologist for
the detection of KF rings. KF rings are almost invariably
present in patients with a neurological presentation, but
even in these patients they may not be found in 5%.15 Large
series of patients with WD show that KF rings are present in
only 50% to 62% of patients with mainly hepatic disease at
the time of diagnosis.16
24 Hour Urinary Copper
Very useful and relatively simple screening test for
WD. Urinary copper is derived from the circulating plasma
free copper. The conventional level taken as diagnostic of
WD is greater than 100 µg/24 hours in symptomatic
patients.17 Recent studies indicate that basal 24-hour urinary
copper excretion may be less than 100 µg at presentation in
16% to 23% of patients diagnosed with WD.18 In asympto-
matic subjects, where copper is still accumulating in the
liver, urinary copper may still be in the normal range. 
Serum Ceruloplasmin Concentration 
This should be considered as a screening test in all
suspected WD patients. 5-15% of individuals with WD may
have normal or only slightly reduced ceruloplasmin, where-
as 10-20% of heterozygotes may have reduced serum ceru-
loplasmin. A serum ceruloplasmin level less than 20 mg/dL
has been considered consistent with WD and diagnostic if
associated with KF rings.19 Most reports indicate that 90%
to 100% of patients had serum ceruloplasmin in the subnor-
mal range.20
Serum Free-Copper Concentration 
Routinely, total serum copper (ceruloplasmin copper
plus free copper) are frequently obtained as a screening test
for WD but is actually of little real value. Determination of
free serum copper directly measures the unbound copper in
the blood, which is typically elevated in symptomatic WD
patients and has been proposed as a useful diagnostic test of
WD.10 It is elevated above 25 µg/dL in most untreated
patients.21 The serum non-ceruloplasmin copper concentra-
tion may be elevated in acute liver failure of any etiology,
not only WD.
Liver Copper Concentration 
This is the single most sensitive and accurate test for
WD. Hepatic copper content will be elevated in virtually all
individuals with WD, even those who are clinically asymp-
tomatic. Hepatic copper content 250 µg/g dry weight
remains the best biochemical evidence for WD. Elevated
hepatic copper itself is not pathognomonic for WD and can
occur in other liver diseases, particularly primary biliary cir-
rhosis, biliary atresia, primary sclerosing cholangitis, Indian
childhood cirrhosis, and chronic active hepatitis. This test is
most important in younger patients in whom hepatocellular
copper is mainly cytoplasmic and thus undetectable by rou-
tine histochemical methods.19
Neuroimaging Studies 
Magnetic resonance imaging (MRI) is a more sensi-
tive indicator of brain involvement in WD. Basal ganglia
are the most consistently involved brain area, with the brain
stem and thalamus also frequently affected. Increased signal
intensity on T2-weighetd images is the characteristic abnor-
mality.22 Significant abnormalities on brain imaging may
of WD is suspicion of the disease, when the diagno-
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Serum Ceruloplasmin Concentration 
This should be considered as a screening test in all
suspected WD patients. 5-15% of individuals with WD may
have normal or only slightly reduced ceruloplasmin, where-
as 10-20% of heterozygotes may have reduced serum ceru-
loplasmin. A serum ceruloplasmin level less than 20 mg/dL
has been considered consistent with WD and diagnostic if
associated with KF rings.19 Most reports indicate that 90%
to 100% of patients had serum ceruloplasmin in the subnor-
mal range.20
Serum Free-Copper Concentration 
Routinely, total serum copper (ceruloplasmin copper
plus free copper) are frequently obtained as a screening test
for WD but is actually of little real value. Determination of
free serum copper directly measures the unbound copper in
the blood, which is typically elevated in symptomatic WD
patients and has been proposed as a useful diagnostic test of
WD.10 It is elevated above 25 µg/dL in most untreated
patients.21 The serum non-ceruloplasmin copper concentra-
tion may be elevated in acute liver failure of any etiology,
not only WD.
Liver Copper Concentration 
This is the single most sensitive and accurate test for
WD. Hepatic copper content will be elevated in virtually all
individuals with WD, even those who are clinically asymp-
tomatic. Hepatic copper content 250 µg/g dry weight
remains the best biochemical evidence for WD. Elevated
hepatic copper itself is not pathognomonic for WD and can
occur in other liver diseases, particularly primary biliary cir-
rhosis, biliary atresia, primary sclerosing cholangitis, Indian
childhood cirrhosis, and chronic active hepatitis. This test is
most important in younger patients in whom hepatocellular
copper is mainly cytoplasmic and thus undetectable by rou-
tine histochemical methods.19
Neuroimaging Studies 
Magnetic resonance imaging (MRI) is a more sensi-
tive indicator of brain involvement in WD. Basal ganglia
are the most consistently involved brain area, with the brain
stem and thalamus also frequently affected. Increased signal
intensity on T2-weighetd images is the characteristic abnor-
mality.22 Significant abnormalities on brain imaging may
even be present in some individuals prior to the onset of
symptoms.23 Serum aminotransferases activities are gener-
ally abnormal in WD, except at a very early age.19
Incorporation of Radiocopper (64CU) into Ceruloplasmin
test is now rarely used because of obtaining isotopes.
Haplotype analysis (molecular genetic studies), is commer-
cially available, and can be utilized for screening of family
members of an affected individual.24
Treatment
Treatment of WD can be stratified into four primary
approaches: dietary therapy (by reducing copper content in
diet), therapy to reduce intestinal copper absorption (by
zinc, and tetrathiomolybdate), therapy to increase copper
chelation and elimination (by penicillamine, trientene, and
BAL), and liver transplantation. Table 3 gives the therapeu-
tic options for WD.
Diet 
Foods with very high concentrations of copper
(shellfish, nuts, chocolate, mushrooms, and organ meats)
generally should be avoided, at least in the first year of treat-
ment. Diets deficient in copper may delay the onset of the
disease and control disease progression, but dietary man-
agement is not recommended as sole therapy.25
Zinc 
Zinc is currently reserved for maintenance therapy;
it has also been used as initial therapy, in asymptomatic or
presymptomatic patients, and appears to be equally effec-
tive as penicillamine.26 Although zinc is almost always
well-tolerated, adverse effect may occur. Neurological dete-
rioration is uncommon with zinc.26 Urinary excretion of
zinc may be measured from time to time to check compli-
ance. Adequacy of treatment with zinc is judged by clinical
clinical and biochemical improvement, by measur-
ing 24-h urinary copper (should be less than 75 µg / 24
hours), and by normalization of serum free-copper concen-
tration on stable treatment.19
D-Penicillamine 
The sulfhydryl moiety of the penicillamine molecule
binds copper and forms penicillamine-copper complexes
that are excreted in the urine. Penicillamine is indicated as
the primary therapy of symptomatic patients with hepatic or
neurologic/psychiatric disease. In the asymptomatic
homozygote, penicillamine can be used. Before starting
therapy baseline copper metabolic parameters should be
collected (24-h urinary excretion, serum free copper, exam-
ination for KF rings) for future follow-up. Complete blood
count and platelet count should also be obtained before
treatment is begun. Pretreatment urine analysis and 24-h
urine protein excretion are also recommended because of
the possibility of penicillamine-induced proteinuria or
nephritic syndrome.27
The drug is administered 1 hour before or 2 or more
hour after meals because food diminishes the amount of D-
penicillamine absorbed by gastrointestinal tract.
One troublesome aspect of penicillamine is its
propensity to produce initial deterioration in neurological
function in 10% to 50% of penicillamine-treated WD
patients, after treatment is begun. Half of those in whom
neurological deterioration occurs on initiation of penicil-
lamine therapy do not fully recover to their base line level
of functioning.28 The reason for this neurological deteriora-
tion is uncertain. Mobilization of copper from the liver with
subsequent redistribution to the brain has been suggested.29
Regular supplementation with pyridoxine (25 to 50
mg daily) is required because of an antipyridoxine effect of
penicillamine, especially during pregnancy, during a growth
spurt, or with dietary deficiency.28
Trientine
Trientine and penicillamine may mobilize different
pools of body copper. Whether trientine is a weaker chela-
tor of copper than penicillamine is controversial. Trientine
is indicated especially in patients who are intolerant of peni-
cillamine or have clinical features indicating potential intol-
erance (history of renal disease of any sort, congestive
spleenomegaly causing severe thrombocytopenia, or
autoimmune tendency).30 Trientine has also been shown to
be an effective initial therapy for patients with WD.31
Trientine appears to be a less toxic compound.
Neurologic worsening after beginning treatment with trien-
tine has been reported but appears much less common than
with penicillamine. Adequacy of treatment with trientine is
monitored by measuring 24-hour urinary copper. This
should run in the vicinity of 200 to 500 µg per day on treat-
ment. 
Tetrathiomolybdate (TM)
Tetrathiomolybdate is another chelating agent cur-
rently undergoing evaluation as an initial treatment of
patients with neurologic symptoms. The first reports on the
use of tetrathiomolybdate in this setting suggest no worsen-
ing of neurologic symptoms and a rapid reduction in circu-
lating free copper during the first 8 weeks of therapy.32
Experience with TM in the treatment of WD is cur-
rently limited and experimental. In United States of
America, commercially it is not available.
Orthotopic Liver Transplantation (OLT) 
This may be a lifesaving and curative treatment for
WD and is indicated for all WD patients with decompensat-
ed liver disease unresponsive to medical therapy. It is the
only effective option for those who present with fulminant
hepatic failure. One-year survival following OLT ranges
from 79% to 87%, and those who survive this early period
continue to survive long term.33 Liver transplantation is not
recommended as primary treatment for neurologic WD
since the liver disease is stabilized by medical therapy in
most of these individuals, and outcomes with liver trans-
plantation are not always beneficial.33 Family Screening
First degree relatives of any patient with WD must be
screened for WD. Assessment should include history of liver
disease and subtle features of neurological involvement slip
lamp examination for KF rings, serum free copper, ceruloplas-
min, liver function tests and 24-h urinary copper. Liver biopsy
with liver copper concentration should be checked in individu-
als with subnormal ceruloplasmin and abnormal liver function
in the absence of KF rings. If available, haplotype studies
should be obtained as a primary screening. Treatment should
be initiated for all individuals over 3 to 4 years old identified as
patients by family screening.19
Prognosis
Untreated WD is progressive and fatal. The greater
danger is that the patient remains undiagnosed and dies
untreated. The prognosis for patients who comply with
pharmacotherapy is excellent, even if cirrhosis or chronic
hepatitis is present at the time of diagnosis.34 In the acute
neurological form the prognosis is poor. Dystonia also car-
ries a poor prognosis, being little affected by chelation ther-
apy. The fulminant cases are frequently fatal despite chela-
tion therapy. The final prognosis also depends on the
response to 6 months of  continuous penicillamine therapy.
At present, there is no better way to judge the extent of
reversibility of a patient's disease than awaiting a response
At present, there is no better way to judge the extent
of reversibility of a patient's disease than awaiting a
response to treatment. 
Practice Guidelines and Recommendations
Recently the American Association for the Study of
Liver Diseases (AASLD) has published practice guide-
lines.19 Some important recommendations are: (1) WD
should be considered in any individual between the ages of
3 and 45 years with liver abnormalities of uncertain cause.
(2) KF rings should be sought by slit-lamp examination by
an experienced ophthalmologist. The absence of KF rings
does not exclude the diagnosis of WD. (3) An extremely low
serum ceruloplasmin level (<5 mg/dL) should be taken as
strong evidence for the diagnosis of WD. (4) 24-hour uri-
nary copper should be measured in WD, and it is typically
greater than 100 µg in symptomatic patients. (5) Neurologic
evaluation and radiologic imaging of the brain, preferably
by MRI, should be considered prior to treatment in all
patients with neurologic WD. (6) First-degree relatives of
any patient newly diagnosed with WD must be screened
thoroughly for WD. (7) Initial treatment for symptomatic
patients should include a chelating agent (penicillamine or
trientine). (8) Treatment of presymptomatic patients or
maintenance therapy of successfully treated symptomatic
patients can be accomplished with the chelating agent peni-
cillamine or trientine, or zinc. (9) Patients with fulminant
hepatic failure or patients with severe liver disease unre-
sponsive to chelation treatment should be treated with liver
transplantation. (10) Treatment is lifelong and should not be
discontinued, unless a liver transplantation has been per-
formed.
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